Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias

Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR-ABL inhibitor, nilotinib (AMN107), is significantly more potent against BCR-ABL than imatinib, and is active against many imat...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Weisberg, Ellen, Catley, Laurie, Wright, Renee D., Moreno, Daisy, Banerji, Lolita, Ray, Arghya, Manley, Paul W., Mestan, Juergen, Fabbro, Doriano, Jiang, Jingrui, Hall-Meyers, Elizabeth, Callahan, Linda, DellaGatta, Jamie L., Kung, Andrew L., Griffin, James D.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2007
Предметы:
Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1801049/
https://ncbi.nlm.nih.gov/pubmed/17068153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-026377
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы